Literature DB >> 4198296

Double-blind clinical evaluation of mazindol, dextroamphetamine, and placebo in treatment of exogenous obesity.

E A Defelice, L B Chaykin, A Cohen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4198296

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN： 0011-393X


× No keyword cloud information.
  4 in total

1.  Mazindol-induced lithium toxicity.

Authors:  M S Hendy; A F Dove; P G Arblaster
Journal:  Br Med J       Date:  1980-03-08

Review 2.  Anorectic drugs: use in general practice.

Authors:  D Craddock
Journal:  Drugs       Date:  1976       Impact factor: 9.546

3.  Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder.

Authors:  Eric Konofal; Wei Zhao; Cédric Laouénan; Michel Lecendreux; Florentia Kaguelidou; Lila Benadjaoud; France Mentré; Evelyne Jacqz-Aigrain
Journal:  Drug Des Devel Ther       Date:  2014-12-01       Impact factor: 4.162

Review 4.  Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.

Authors:  Rosa Camila Lucchetta; Bruno Salgado Riveros; Roberto Pontarolo; Rosana Bento Radominski; Michel Fleith Otuki; Fernando Fernandez-Llimos; Cassyano Januário Correr
Journal:  Clinics (Sao Paulo)       Date:  2017-05       Impact factor: 2.365
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.